Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides continuous inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth. If approved, RAD001 will become the first oral, once-daily therapy that targets mTOR to treat advanced kidney cancer.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003.

In addition to renal cell carcinoma (RCC), RAD001 is being evaluated as a single agent or in combination with existing therapies in neuroendocrine tumors, lymphoma, breast, gastric, lung and other cancers, as well as tuberous sclerosis.

About renal cell carcinoma (RCC)

In the US, kidney cancer accounts for approximately 3% of all adult cancers. RCC, the most common type of kidney cancer, accounts for approximately 90% of malignant kidney tumors. In RCC, cancer cells develop in the lining of the kidney's tubes and grow into a tumor.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "potential", "proposed", "believe", "should", "priority review", "potentially", "encouraged", "committed", "may", "suggest", or similar expressions, or by express or implied discussions regarding potential marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other fact
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Decision Resources, one of the ... and healthcare issues, finds that the cost of ... and side-effect profile, are cited most frequently by ... of Avastin for non-small-cell lung cancer treatment in ... ,, The new Special European Physician & Payer ...
(Date:12/17/2009)... HUNTINGTON BEACH, California and AMSTERDAM, December 17 /PRNewswire/ ... announced today that,the US Food and Drug Administration ... all ages. MammaPrint is the only FDA-cleared,breast cancer ... the,past three years, the FDA has issued four ... service. , "This FDA ...
(Date:12/17/2009)... Calif., Dec. 17 Frost & ... North American Healthcare Innovation Award in molecular ... for its commitment to providing innovative technologies ... Since its incorporation in 2004, IntelligentMDx has ... approach to make tests that are clinically ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3FDA Broadens Clearance for Agendia's MammaPrint(R) 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5More Gene Mutations Linked to Autism Risk 4655 1More Gene Mutations Linked to Autism Risk 4655 2More Gene Mutations Linked to Autism Risk 4655 3More Gene Mutations Linked to Autism Risk 4655 4HIV Testing Day Set for Saturday in U S 50162 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 3
... EPOC Results Published in March 22 Issue ... March 20 Sanofi-aventis,today announced that efficacy ... Intergroup study published in the March 22 ... patients Eloxatin(R) (oxaliplatin injection) in,combination with 5-fluorouracil/leucovorin ...
... targeting interleukin-6 receptors, ACTEMRA provides significant ... existing therapies -, NUTLEY, N.J., March 20 ... (tocilizumab) experienced,significant and rapid reduction in the signs ... published in this week,s issue of The Lancet. ...
Other Medicine Technology:Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 2International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 3International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 4International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 5
(Date:12/17/2009)... heels of unveiling the new Stadium to the Sea ... officials today announced a larger-than-ever charity program that will ... from cancer research to gang intervention to cleaning up ... line with the vision of Marathon Owner Frank McCourt, ... a huge philanthropic force in the community. McCourt envisions ...
(Date:12/17/2009)... The following feature is by Devon Herrick, PhD, ... ,, People often assume they have little control ... After all, sickness cannot be scheduled, doctors prescribe treatments ... percent of Americans. However, there are many overlooked ways ... care you need. ,, Cut your ...
(Date:12/17/2009)... DAYTON, Ohio, Dec. 17 Good Samaritan Hospital ... pelvic health issues with the launch of the Good ... ,, The center is designed to help treat two ... incontinence) and slippage of the bladder, uterus or rectum ... some degree of urinary leakage and one out of ...
(Date:12/17/2009)... -- The National Council on Disability (NCD) ... Marriott Houston, 5150 Westheimer, Houston, TX, beginning at 8:30 ... 11:00 a.m. on Thursday, January 21, 2010. This meeting ... it is vital to hear from communities around the ... people with disabilities. This meeting will provide another opportunity ...
(Date:12/17/2009)... show that Chinese research output has increased from just ... 2008. , Faculty of 1000, which selects only ... more than 530 papers from Chinese universities and institutes ... in 2004, this increased by over fourfold in 2008 ... , Jane Hunter, Managing Director of Faculty of 1000, ...
Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:China rapidly catching up in research impact 2
... invites customers to just ,have fun, and use social ... 6 Baxa Corporation, a leading developer of technology ... medications, has joined the social media craze by hosting ... Group. More and more healthcare facilities, medical device ...
... MULTIPLE LIFESTYLE-BASED OFFERINGSLOS ANGELES, April 6 ... FVRL), which through its wholly-owned operating subsidiary, ... Personal Health Records ("PHRs") ( www.mymedicalrecords.com ... storage solutions ( www.myesafedepositbox.com ), ...
... and B-to-C Firm Starts with Several Accounts; Membership ... 6 Feintuch Communications, Inc. ( www.feintuchcommunications.com ... industry veteran and former journalist Henry Feintuch, has ... Avenue in New York City.(Logo: ...
... 2009 New head-to-head clinical trial results demonstrate that ... The five studies conducted by Johnson & Johnson ... during the 87th General Session and Exhibition of the ... , REACH ULTRACLEAN Floss removes up to two ...
... for the Medical Waste Treatment MarketMOUNTAIN VIEW, Calif., April ... medical waste treatment market, Frost & Sullivan recognizes BioMedical ... Frost & Sullivan Award for Product Innovation of the ... innovation, as evidenced by its introduction of the Demolizer(R) ...
... EL SEGUNDO, Calif., April 6 DaVita ... named winner of the 2009 Recruiting Department of the ... ( http://www.ere.net ) presents Recruiting Excellence Awards annually to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO )The ...
Other Medicine News:Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 2Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 3Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 2Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 3Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 4Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 2Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 3Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 4Health News:New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products 2Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 2Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 3Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 4Health News:DaVita Wins Recruiting Department of the Year Award 2
... SonoVue, a new Contrast ... aqueous suspension of stabilized SF6 ... microbubbles is between 1 and ... is between 2 and 5 ...
... well-established, second-generation ultrasound medical diagnostic product with ... borders of the heart. This allows doctors ... the heart during an ultrasound scanning procedure, ... heart condition and providing guidance for the ...
... new tibial guide is designed for accuracy ... choose between "point" or "elbow" aimers and ... creation of the tibial tunnel. The system ... features and the reproducibility and accuracy gained ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Medicine Products: